|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
However, we found the significant association of RNASEL Asp541Glu polymorphism with sporadic PCa (Glu/Glu vs. Asp/Asp: OR 1.29, 95% CI: 1.04-1.59, P = 0.02; Glu/Asp vs. Asp/Asp: OR 1.24, 95% CI: 1.03-1.50, P = 0.03).
|
21656378 |
2012 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We found no evidence of association between R462Q and D541E polymorphisms and prostate cancer risk in our case/control analysis.
|
18189233 |
2008 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Nevertheless, rs627928 was reported to promote the development of prostate cancer (T vs. G: OR=1.08, 95% CI=1.01-1.15; TT+TG vs. GG: OR=1.14, 95% CI=1.03-1.25) in allele and recessive models in overall populations.
|
31686670 |
2019 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our study provides the proof-of-principle that some of the genetic variants (such as rs486907, rs627928 and rs2127565) in genes RNASEL, MSR1 and ELAC2 can be used as predictors of aggressiveness and progression of PCa.
|
26251261 |
2015 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We examined polymorphisms within ELAC2 (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and RNASEL (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 prostate cancer-free controls using pyrosequencing assays.
|
16114055 |
2006 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by <2-fold in Caucasians, regardless of family history of the disease.
|
17020975 |
2006 |
|
rs627928
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We found a marginally significant inverse association between the missense mutation D541E and sporadic prostate cancer risk (odds ratio, 0.77; 95% confidence interval, 0.59-1.00) and reduced risk of prostate cancer in carriers of two different haplotypes being completely discordant.
|
15534086 |
2004 |
|
rs74315364
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using 1624 prostate cancer cases and 801 unaffected controls, the truncating mutation E265X and five common sequence variants, including the two missense mutations R462Q and D541E, were evaluated for association between genotypes/haplotypes and prostate cancer risk.
|
15534086 |
2004 |
|
rs74315364
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We identified only two sib pairs (1.4% of our families) cosegregating conspicuous RNASEL variants with prostate cancer: the nonsense mutation E265X, and a new amino-acid substitution (R400P) of unknown functional relevance.
|
15714208 |
2005 |
|
rs74315364
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Meta-analyses revealed significant associations of prostate cancer with MSR1 IVS7delTTA, -14,742 A>G, and Arg293X in European Americans; Asp174Tyr in African Americans; RNASEL Arg462Gln in European American's overall and in family history-negative disease; and Glu265X in family history-positive European Americans.
|
15824169 |
2005 |
|
rs1360698171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Evaluation of xenotropic murine leukemia virus and its R426Q polymorphism in patients with prostate cancer in Kerman, southeast of Iran.
|
23098452 |
2012 |
|
rs143544690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel variant (K294E) was identified in a single heterozygous individual with prostate cancer.
|
18189233 |
2008 |
|
rs56250729
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two RNASEL SNPs were associated with overall increases in prostate cancer risk (OR = 1.13 for each variant allele of rs12723593; OR = 1.88 for any variant allele of rs56250729).
|
21360564 |
2011 |